Novel SHP-1 inhibitors tyrosine phosphatase inhibitor-1 and analogs with preclinical anti-tumor activities as tolerated oral agents

Journal of Immunology

Volumn 184, Issue 11, 2010, Pages 6529-6536

  Kundu, Suman ^a   Fan, Keke ^a   Cao, Mingli ^a   Lindner, Daniel J ^a,b   Zhao, Zhizhaung Joe ^c   Borden, Ernest ^a,b   Yi, Taolin ^a,b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b TAUSSIG CANCER INSTITUTE   (United States)

^c UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD45 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 2; MITOGEN ACTIVATED PROTEIN KINASE 1; PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE INHIBITOR; PROTEIN TYROSINE PHOSPHATASE SHP 1; STIBOGLUCONATE SODIUM; ANTINEOPLASTIC AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD; CANCER CELL CULTURE; CANCER INHIBITION; CANCER THERAPY; CELL CULTURE; CELL GROWTH; COLON CANCER; CONTROLLED STUDY; CULTURAL ANTHROPOLOGY; CYTOKINE PRODUCTION; FEMALE; HUMAN; HUMAN CELL; IMMUNITY; IMMUNOCOMPETENT CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL LINE; MELANOMA; MELANOMA B16; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; SPLEEN; SURVIVAL; T LYMPHOCYTE; TUMOR GROWTH; ANIMAL; C57BL MOUSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; EXPERIMENTAL NEOPLASM; LYMPHOCYTE ACTIVATION; MOUSE; ORAL DRUG ADMINISTRATION; WESTERN BLOTTING;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; JURKAT CELLS; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 6;

EID: 77953417324     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0903562     Document Type: Article

References (75)

1. Rosenberg, S. A. 2004. Shedding light on immunotherapy for cancer. N. Engl. J. Med. 350: 1461-1463.
2. Rosenberg, S. A. 2000. Interleukin-2 and the development of immunotherapy for the treatment of patients with cancer. Cancer J. Sci. Am. 2000: S2-S7.
3. Atkins, M. B. 2006. Cytokine-based therapy and biochemotherapy for advanced melanoma. Clin. Cancer Res. 12: 2353s-2358s.
4. Atkins, M. B., M. T. Lotze, J. P. Dutcher, R. I. Fisher, G. Weiss, K. Margolin, J. Abrams, M. Sznol, D. Parkinson, M. Hawkins, et al. 1999. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol. 17: 2105-2116.
5. Pentcheva-Hoang, T., E. Corse, and J. P. Allison. 2009. Negative regulators of T-cell activation: potential targets for therapeutic intervention in cancer, autoimmune disease, and persistent infections. Immunol. Rev. 229: 67-87.
6. Weiss, A. 2009. TCR signal transduction: opening the black box. J. Immunol. 183: 4821-4827.
7. Paulos, C. M., A. Kaiser, C. Wrzesinski, C. S. Hinrichs, L. Cassard, A. Boni, P. Muranski, L. Sanchez-Perez, D. C. Palmer, Z. Yu, et al. 2007. Toll-like receptors in tumor immunotherapy. Clin. Cancer Res. 13: 5280-5289.
8. Rosenberg, S. A., N. P. Restifo, J. C. Yang, R. A. Morgan, and M. E. Dudley. 2008. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat. Rev. Cancer 8: 299-308.
9. Sarnaik, A. A., and J. S. Weber. 2009. Recent advances using anti-CTLA-4 for the treatment of melanoma. Cancer J. 15: 169-173.
10. Druker, B. J. 2004. Molecularly targeted therapy: have the floodgates opened? Oncologist 9: 357-360.
11. de Jonge, M. J., and J. Verweij. 2006. Multiple targeted tyrosine kinase inhibition in the clinic: all for one or one for all? Eur. J. Cancer 42: 1351-1356.
12. Motzer, R. J., B. I. Rini, R. M. Bukowski, B. D. Curti, D. J. George, G. R. Hudes, B. G. Redman, K. A. Margolin, J. R. Merchan, G. Wilding, et al. 2006. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295: 2516-2524.
13. Tonks, N. K. 2006. Protein tyrosine phosphatases: from genes, to function, to disease. Nat. Rev. Mol. Cell Biol. 7: 833-846.
14. Neel, B. G., H. Gu, and L. Pao. 2003. The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling. Trends Biochem. Sci. 28: 284-293.
15. Zhang, Z. Y. 2002. Protein tyrosine phosphatases: structure and function, substrate specificity, and inhibitor development. Annu. Rev. Pharmacol. Toxicol. 42: 209-234.
16. Lazo, J. S., and P. Wipf. 2003. Small molecule regulation of phosphatase-dependent cell signaling pathways. Oncol. Res. 13: 347-352.
17. Yi, T., and D. J. Lindner. 2008. The role and target potential of protein tyrosine phosphatases in cancer. Curr. Oncol. Rep. 10: 114-121.
18. Zhang, J., A. K. Somani, and K. A. Siminovitch. 1999. Roles of the SHP-1 tyrosine phosphatase in the negative regulation of cell signalling. Semin. Immunol. 12: 361-378.
19. Joliat, M. J., and L. D. Shultz. 2001. The molecular bases of spontaneous immunological mutations in the mouse and their homologous human diseases. Clin. Immunol. 101: 113-129.
20. Long, E. O. 1999. Regulation of immune responses through inhibitory receptors. Annu. Rev. Immunol. 17: 875-904.
21. Dolton, G. M., J. G. Sathish, and R. J. Matthews. 2006. Protein tyrosine phosphatases as negative regulators of the immune response. Biochem. Soc. Trans. 34: 1041-1045.
22. Tartaglia, M., E. L. Mehler, R. Goldberg, G. Zampino, H. G. Brunner, H. Kremer, I. van der Burgt, A. H. Crosby, A. Ion, S. Jeffery, et al. 2001. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat. Genet. 29: 465-468.
23. Tartaglia, M., K. Kalidas, A. Shaw, X. Song, D. L. Musat, I. van der Burgt, H. G. Brunner, D. R. Bertola, A. Crosby, A. Ion, et al. 2002. PTPN11 mutations in Noonan syndrome: molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity. Am. J. Hum. Genet. 70: 1555-1563.
24. Tartaglia, M., and B. D. Gelb. 2005. Germ-line and somatic PTPN11 mutations in human disease. Eur. J. Med. Genet. 48: 81-96.
25. Araki, T., M. G. Mohi, F. A. Ismat, R. T. Bronson, I. R. Williams, J. L. Kutok, W. Yang, L. I. Pao, D. G. Gilliland, J. A. Epstein, and B. G. Neel. 2004. Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation. Nat. Med. 10: 849-857.
26. Saha, S., A. Bardelli, P. Buckhaults, V. E. Velculescu, C. Rago, B. St Croix, K. E. Romans, M. A. Choti, C. Lengauer, K. W. Kinzler, and B. Vogelstein. 2001. A phosphatase associated with metastasis of colorectal cancer. Science 294: 1343-1346.
27. Easty, D., W. Gallagher, and D. C. Bennett. 2006. Protein tyrosine phosphatases, new targets for cancer therapy. Curr. Cancer Drug Targets 6: 519-532.
28. Berman, J. D. 1988. Chemotherapy for leishmaniasis: biochemical mechanisms, clinical efficacy, and future strategies. Rev. Infect. Dis. 10: 560-586.
29. Pathak, M. K., and T. Yi. 2001. Sodium stibogluconate is a potent inhibitor of protein tyrosine phosphatases and augments cytokine responses in hemopoietic cell lines. J. Immunol. 167: 3391-3397.
30. Lorenz, U. 2009. SHP-1 and SHP-2 in T cells: two phosphatases functioning at many levels. Immunol. Rev. 228: 342-359.
31. David, M., H. E. Chen, S. Goelz, A. C. Larner, and B. G. Neel. 1995. Differential regulation of the alpha/beta interferon-stimulated Jak/Stat pathway by the SH2 domain-containing tyrosine phosphatase SHPTP1. Mol. Cell. Biol. 15: 7050-7058.
32. Jiao, H., W. Yang, K. Berrada, M. Tabrizi, L. Shultz, and T. Yi. 1997. Macrophages from motheaten and viable motheaten mutant mice show increased proliferative responses to GM-CSF: detection of potential HCP substrates in GM-CSF signal transduction. Exp. Hematol. 25: 592-600.
33. Migone, T. S., N. A. Cacalano, N. Taylor, T. Yi, T. A. Waldmann, and J. A. Johnston. 1998. Recruitment of SH2-containing protein tyrosine phosphatase SHP-1 to the interleukin 2 receptor; loss of SHP-1 expression in human T-lymphotropic virus type I-transformed T cells. Proc. Natl. Acad. Sci. USA 95: 3845-3850.
34. Fan, K., M. Zhou, M. K. Pathak, D. J. Lindner, C. Z. Altuntas, V. K. Tuohy, E. C. Borden, and T. Yi. 2005. Sodium stibogluconate interacts with IL-2 in anti- Renca tumor action via a T cell-dependent mechanism in connection with induction of tumor-infiltrating macrophages. J. Immunol. 175: 7003-7008.
35. Fan, K., E. C. Borden, and T. Yi. 2009. Interferon-gamma is induced in human peripheral blood immune cells in vitro by sodium stiboglucnate/ interleukin-2 and mediates its ant-tumor activity in vivo. J. Interferon Cytokine Res. 29: 451-460.
36. Yi, T., M. K. Pathak, D. J. Lindner, M. E. Ketterer, C. Farver, and E. C. Borden. 2002. Anticancer activity of sodium stibogluconate in synergy with IFNs. J. Immunol. 169: 5978-5985.
37. Li, J., D. J. Lindner, C. Farver, E. C. Borden, and T. Yi. 2007. Efficacy of SSG and SSG/IFNalpha2 against human prostate cancer xenograft tumors in mice: a role for direct growth inhibition in SSG anti-tumor action. Cancer Chemother. Pharmacol. 60: 341-349.
38. Naing, A., J. Reuben, C. Verschraegen, L. Camacho, S. Stephen, D. Hong, J. Wheler, S. Fu, M. Martinez, L. Akinsanmi, and R. Kurzrock. 2008. Phase I dose-escalation study of sodium stibogluconate (SSG), a protein tyrosine phosphatase inhibitor, combined with interferon-alfa for patients with solid tumors. J. Clin. Oncol. 26: 3011 (Abstr.).
39. Liang, X., W. Meng, T. Niu, Z. Zhao, and G. W. Zhou. 1997. Expression, purification, and crystallization of the catalytic domain of protein tyrosine phosphatase SHP-1. J. Struct. Biol. 120: 201-203.
40. Schneider, U., H. U. Schwenk, and G. Bornkamm. 1977. Characterization of EBV-genome negative "null" and "T" cell lines derived from children with acute lymphoblastic leukemia and leukemic transformed non-Hodgkin lymphoma. Int. J. Cancer 19: 621-626.
41. Fidler, I. J. 1973. Selection of successive tumour lines for metastasis. Nat. New Biol. 242: 148-149.
42. Singh, P., J. P. Walker, C. M. Townsend, Jr., and J. C. Thompson. 1986. Role of gastrin and gastrin receptors on the growth of a transplantable mouse colon carcinoma (MC-26) in BALB/c mice. Cancer Res. 46: 1612-1616.
43. Kripke, M. L. 1979. Speculations on the role of ultraviolet radiation in the development of malignant melanoma. J. Natl. Cancer Inst. 63: 541-548.
44. Gerke, C., S. Falkow, and Y. H. Chien. 2005. The adaptor molecules LAT and SLP-76 are specifically targeted by Yersinia to inhibit T cell activation. J. Exp. Med. 201: 361-371.
45. Haque, S. J., P. Harbor, M. Tabrizi, T. Yi, and B. R. Williams. 1998. Protein-tyrosine phosphatase Shp-1 is a negative regulator of IL-4- and IL-13-dependent signal transduction. J. Biol. Chem. 273: 33893-33896.
46. Yi, T., A. L. Mui, G. Krystal, and J. N. Ihle. 1993. Hematopoietic cell phosphatase associates with the interleukin-3 (IL-3) receptor beta chain and downregulates IL-3-induced tyrosine phosphorylation and mitogenesis. Mol. Cell. Biol. 13: 7577-7586.
47. Yi, T., and J. N. Ihle. 1993. Association of hematopoietic cell phosphatase with c-Kit after stimulation with c-Kit ligand. Mol. Cell. Biol. 13: 3350-3358.
48. Lindner, D. J., E. C. Borden, and D. V. Kalvakolanu. 1997. Synergistic antitumor effects of a combination of interferons and retinoic acid on human tumor cells in vitro and in vivo. Clin. Cancer Res. 3: 931-937.
49. Chiang, G. G., and B. M. Sefton. 2001. Specific dephosphorylation of the Lck tyrosine protein kinase at Tyr-394 by the SHP-1 protein-tyrosine phosphatase. J. Biol. Chem. 276: 23173-23178.
50. Mary, F., C. Moon, T. Venaille, M. L. Thomas, D. Mary, and A. Bernard. 1999. Modulation of TCR signaling by beta1 integrins: role of the tyrosine phosphatase SHP-1. Eur. J. Immunol. 29: 3887-3897.
51. Musci, M. A., S. L. Beaves, S. E. Ross, T. Yi, and G. A. Koretzky. 1997. Surface expression of hemopoietic cell phosphatase fails to complement CD45 deficiency and inhibits TCR-mediated signal transduction in a Jurkat T cell clone. J. Immunol. 158: 1565-1571.
52. Frearson, J. A., and D. R. Alexander. 1998. The phosphotyrosine phosphatase SHP-2 participates in a multimeric signaling complex and regulates T cell receptor (TCR) coupling to the Ras/mitogen-activated protein kinase (MAPK) pathway in Jurkat T cells. J. Exp. Med. 187: 1417-1426.
53. Plas, D. R., R. Johnson, J. T. Pingel, R. J. Matthews, M. Dalton, G. Roy, A. C. Chan, and M. L. Thomas. 1996. Direct regulation of ZAP-70 by SHP-1 in T cell antigen receptor signaling. Science 272: 1173-1176.
54. Binstadt, B. A., D. D. Billadeau, D. Jevremović, B. L. Williams, N. Fang, T. Yi, G. A. Koretzky, R. T. Abraham, and P. J. Leibson. 1998. SLP-76 is a direct substrate of SHP-1 recruited to killer cell inhibitory receptors. J. Biol. Chem. 273: 27518-27523.
55. Aguado, E., M. Martínez-Florensa, and P. Aparicio. 2006. Activation of T lymphocytes and the role of the adapter LAT. Transpl. Immunol. 17: 23-26.
56. Shi, Z. Q., W. Lu, and G. S. Feng. 1998. The Shp-2 tyrosine phosphatase has opposite effects in mediating the activation of extracellular signal-regulated and c-Jun NH2-terminal mitogen-activated protein kinases. J. Biol. Chem. 273: 4904-4908.
57. Fragale, A., M. Tartaglia, J. Wu, and B. D. Gelb. 2004. Noonan syndrome-associated SHP2/PTPN11 mutants cause EGF-dependent prolonged GAB1 binding and sustained ERK2/MAPK1 activation. Hum. Mutat. 23: 267-277.
58. Sieh, M., J. B. Bolen, and A. Weiss. 1993. CD45 specifically modulates binding of Lck to a phosphopeptide encompassing the negative regulatory tyrosine of Lck. EMBO J. 12: 315-321.
59. Ikeda, H., L. J. Old, and R. D. Schreiber. 2002. The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev. 13: 95-109.
60. Becker, Y. 2006. Molecular immunological approaches to biotherapy of human cancers - a review, hypothesis and implications. Anticancer Res. 26(2A): 1113-1134.
61. Beattie, C. W., R. Tissot, and M. Amoss. 1988. Experimental models in human melanoma research: a logical perspective. Semin. Oncol. 15: 500-511.
62. Li, J., D. J. Lindner, C. Farver, E. C. Borden, and T. Yi. 2007. Efficacy of SSG and SSG/IFNalpha2 against human prostate cancer xenograft tumors in mice: a role for direct growth inhibition in SSG anti-tumor action. Cancer Chemother. Pharmacol. 60: 341-349.
63. Keller, T. H., A. Pichota, and Z. Yin. 2006. A practical view of 'druggability'. Curr. Opin. Chem. Biol. 10: 357-361.
64. Melnikova, V. O., S. V. Bolshakov, C. Walker, and H. N. Ananthaswamy. 2004. Genomic alterations in spontaneous and carcinogen-induced murine melanoma cell lines. Oncogene 23: 2347-2356.
65. Traxler, P. M., P. Furet, H. Mett, E. Buchdunger, T. Meyer, and N. Lydon. 1996. 4-(Phenylamino)pyrrolopyrimidines: potent and selective, ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase. J. Med. Chem. 39: 2285-2292.
66. Murray, L. J., T. J. Abrams, K. R. Long, T. J. Ngai, L. M. Olson, W. Hong, P. K. Keast, J. A. Brassard, A. M. O'Farrell, J. M. Cherrington, and N. K. Pryer. 2003. SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin. Exp. Metastasis 20: 757-766.
67. Carlomagno, F., S. Anaganti, T. Guida, G. Salvatore, G. Troncone, S. M. Wilhelm, and M. Santoro. 2006. BAY 43-9006 inhibition of oncogenic RET mutants. J. Natl. Cancer Inst. 98: 326-334.
68. Favre, N., G. Bordmann, and W. Rudin. 1997. Comparison of cytokine measurements using ELISA, ELISPOT and semi-quantitative RT-PCR. J. Immunol. Methods 204: 57-66.
69. Wang, Q., J. Stanley, S. Kudoh, J. Myles, V. Kolenko, T. Yi, R. Tubbs, R. Bukowski, and J. Finke. 1995. T cells infiltrating non-Hodgkin's B cell lymphomas show altered tyrosine phosphorylation pattern even though T cell receptor/CD3-associated kinases are present. J. Immunol. 155: 1382-1392.
70. Yu, W. M., S. Wang, A. D. Keegan, M. S. Williams, and C. K. Qu. 2005. Abnormal Th1 cell differentiation and IFN-gamma production in T lymphocytes from motheaten viable mice mutant for Src homology 2 domain-containing protein tyrosine phosphatase-1. J. Immunol. 174: 1013-1019.
71. Atkins, M. B., J. Dutcher, G. Weiss, K. Margolin, J. Clark, J. Sosman, T. Logan, F. Aronson, J. Mier; and Cytokine Working Group. 2001. Kidney cancer: the Cytokine Working Group experience (1986-2001): part I. IL-2-based clinical trials. Med. Oncol. 18: 197-207.
72. Bascon, J. U. 1998. Vascular leak syndrome: a troublesome side effect of immunotherapy, Immunopharmacology. Immunopharmacology 39: 255-257.
73. Barnard, A. L., F. Farzaneh, J. Gäken, and D. Darling. 2000. Local versus systemic interleukin-2: tumor formation by wild-type and B7-1-positive murine melanoma cells. Cancer Gene Ther. 7: 207-214.
74. Lee, C. H., C. L. Wu, and A. L. Shiau. 2008. Toll-like receptor 4 mediates an antitumor host response induced by Salmonella choleraesuis. Clin. Cancer Res. 14: 1905-1912.
75. Poltorak, A., X. He, I. Smirnova, M. Y. Liu, C. Van Huffel, X. Du, D. Birdwell, E. Alejos, M. Silva, C. Galanos, et al. 1998. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 282: 2085-2088.